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The LCCL-domain is a recently deﬁned protein module present in diverse extracellular multidomain
proteins. Practically nothing is known about the molecular function of these domains; based on func-
tional features of proteins harboring LCCL-domains it has been suggested that these domains might
function as lipopolysaccharide-binding domains. Here we show that the two LCCL-domains of human
CRISPLD2 protein, a lipopolysaccharide-binding serum protein involved in defense against endotoxin
shock, have higher afﬁnity for the lipid A, the toxic moiety of lipopolysaccharides than for ipopoly-
saccharide. Our observation that the LCCL-domains of CRISPLD2 are speciﬁc for the toxic lipid A moiety of
the endotoxin suggests that it may block the interaction between endotoxins and the host endotoxin
receptors without interfering with the development of antibacterial immunity against the polysaccharide
moiety of LPS. We suggest that the anti-inﬂammatory function of CRISPLD2 protein may account for its
role in various pathological and developmental processes.
 2013 The Authors. Published by Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
The LCCL-domain is a recently discovered, conserved protein
module named after its presence in Limulus factor C, cochlear
protein Coch-5b2 and late gestation lung protein Lgl1, the ﬁrst and
best studied multidomain proteins in which this domain-type was
recognized [1]. Recent studies have revealed that Plasmodium
species have several types of extracellular multidomain proteins
containing LCCL-domains and that other genera of Apicomplexa
(including Cryptosporidium, Toxoplasma, Eimeria and Theileria)
contain orthologs of these proteins [2e4].
Very little is known about the molecular function of LCCL-
domains. Based on a survey of the functional features of proteins
harboring LCCL-domains we have suggested earlier that LCCL-Protein LCCL Domain con-
st LCCL domain of CRISPLD2;
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r Masson SAS.Open access under CC BY-domains might function in the innate immune system, possibly
as lipopolysaccharide-binding domains [1,5]. The strongest argu-
ment in favor of this assumptionwas that Limulus factor C has high
afﬁnity for lipopolysaccharides and serves in recognition of gram-
negative bacteria. Another line of evidence for this assumption
came from a survey of structural and functional information about
Lgl1, a late gestation lung protein containing two LCCL-domains [1].
Our analyses suggested that Lgl1 protein might play an important
role in host defense against microbial infection by recognizing
polysaccharides of invading pathogens [1]. Recent studies have
conﬁrmed that the Lgl1 protein (renamed as Cysteine-Rich Secre-
tory Protein LCCL Domain containing 2, CRISPLD2) has high afﬁnity
for lipopolysaccharide and plays a critical role in defense against
endotoxin shock [6].
In the present work we tested the hypothesis that the LCCL-
domains of CRISPLD2 may be involved in the binding of lipopoly-
saccharide by this protein. Our results show that both LCCL-
domains of human CRISPLD2 protein have high afﬁnity for lipid
A, the toxic moiety of lipopolysaccharides.
2. Experimental methods
2.1. Reagents, enzymes, PCR primers, proteins, bacterial strains, cell
lines and media
Restriction enzymes, T4 DNA Ligase and Klenow polymerase
were New England Biolabs products (Beverly, MA, USA). PCR
primers were obtained from Integrated DNA TechnologiesNC-ND license.
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lymerase from Fermentas (Vilnius, Lithuania) or the proof-reading
thermostable polymerase Accuzyme (Bioline, London, UK).
The Pichia pastoris expression system was obtained from Invi-
trogen (Carlsbad, CA, USA), the pCDFDuet-1 bacterial expression
vector was the product of Novagen (Gibbstown, NJ, USA). The
Escherichia coli JM109 bacterial strain was used for DNA propaga-
tion during DNA manipulation steps while bacterial protein
expression was performed in E. coli BL21(DE3).
CM5 sensorchips and the reagents for protein coupling to the
chips were from Biacore AB (Uppsala, Sweden). Lipopolysaccharide
from E. coli 0127:B8 strain and lipid A from E. coli F583 strain were
purchased from SigmaeAldrich (St. Louise, MO, USA).
2.2. Protein analyses
The composition of protein samples was analyzed by SDS-PAGE
under both reducing and nonreducing conditions. The gels were
stained with Coomassie brilliant Blue G-250.
The concentrations of the recombinant proteins were deter-
mined using extinction coefﬁcients calculated with the online
protein analysis tool, Protparam (http://us.expasy.org/tools/
protparam.html). We have used the following extinction co-
efﬁcients: CRISPLD2_LCCL1: 6335 M1 cm1, CRISPLD2_LCCL2:
11835 M1 cm1, CRISPLD2_LCCL1þ2: 18170 M1 cm1.
N-terminal sequencing was performed on an Applied Bio-
systems 471A protein sequencer with an on-line ABI 120A phe-
nyltiohydantoin (PTH) analyzer.
2.3. Surface plasmon resonance analysis
Surface plasmon resonancemeasurements were performed on a
BIACORE X (GE Healthcare, Stockholm, Sweden) instrument. Pro-
teins to be immobilized were dissolved in 50 mM sodium acetate,
pH 4.5 and 50 ml of 2.6 mM CRISPLD2_LCCL1þ2, or 70 ml of 2.5 mM
CRISPLD2_LCCL1, or 35 ml of 67.5 mM CRISPLD2_LCCL2 solutions
were injected with a 5 ml/min ﬂow rate on a CM5 sensor chip
activated by the amine coupling method according to the in-
structions of the manufacturer.
Stock solutions of 2.5 mg/ml of lipopolysaccharide from E. coli
0127:B8 strain, 200 mM of diphosphoryl Lipid A from E. coli F583
strain were prepared in 20 mM HEPES buffer, pH 7.5, containing
150 mM NaCl, 5 mM EDTA and 0.005% Tween 20. The solutions
were sonicated at 37 C for 15 min.
For interaction measurements 80 ml aliquots of different con-
centrations of lipopolysaccharide or lipid A solutions were injected
over the sensorchips with a 20 ml/min ﬂow rate, followed by
10 min ﬂow of buffer. Binding and washes were performed in
20 mM HEPES buffer, pH 7.5 containing 150 mM NaCl, 5 mM EDTA
and 0.005% Tween 20. After each cycle the chips were regenerated
by injection of 20 ml 50 mM NaOH with 60 ml/min ﬂow rate. The
injected lipopolysaccharide or lipid A solutions were always diluted
and thoroughly vortexed just before injection.
Control ﬂow cells were prepared by executing the coupling re-
action in the presence of coupling buffer alone. Control ﬂow cells
were used to obtain control sensorgrams showing non-speciﬁc
binding to the surface as well as refractive index changes result-
ing from changes in bulk properties of the solution. Control sen-
sorgrams were subtracted from sensorgrams obtained with
immobilized ligand. To correct for differences between the reaction
and reference surfaces we have also subtracted the average of
sensorgrams obtained with blank running buffer injections.
The kinetic parameters for each interaction were determined by
ﬁtting the experimental data with BIAevaluation software 4.0. The
datawere ﬁtted to amodel of 1:1 Langmuir interaction. To calculaterate constants of the association reactions and the equilibrium
dissociation constants of the interactions of LCCL-domains with
lipopolysaccharide and lipid A one must know the effective mo-
lecular weight of these compounds. However, LPS (lipopolysac-
charide from E. coli 0127:B8 strain, SigmaeAldrich, St. Louise, MO,
USA) is heterogeneous and tends to form aggregates of varying
sizes. In the presence of strong surface active agents and in the
absence of divalent cations bacterial endotoxins consist of 10e
20 kDa macromolecules, whereas in the absence of surface active
agents lipopolysaccharide forms micellar structures with a molec-
ular weight of approximately 1000 kDa. Since we studied the
interaction of lipopolysaccharide with LCCL-domains in solutions
containing 5 mM EDTA and 0.005% Tween 20 we calculated kinetic
constants based on the assumption that the effective molecular
weight of lipopolysaccharide is 20 kDa.
2.4. Expression of the two LCCL-domains of human CRISPLD2
The DNA encoding both LCCL-domains of human CRISPLD2
protein (residues Met284-Gln497 of full-length protein) was
ampliﬁed from human placenta cDNA library with the primer pair:
50 GCCGAATTCATGACCCAAGTCGTCAGATGTG 30 and 50 GCCTCTA-
GATGCCTGACAGCAAAGATCCGG 30.
The ampliﬁed DNAwas digested with EcoRI and XbaI restriction
enzymes and ligated into the pPICZalphaA expression vector
digested with EcoRI-XbaI enzymes. The resulting expression
cassette consists of the inducible AOX1 promoter of the alcohol
oxidase 1 gene of P. pastoris, the yeast alpha-mating factor secretion
signal sequence, the DNA insert encoding both LCCL-domains of
human CRISPLD2, a myc-epitope, a hexahistidine His tag and the 30
termination signal of the AOX1 gene. The pPICZalphaA expression
plasmid contains the zeocin resistance gene for easy selection of
positive transformants. The molecular mass calculated for the
amino acid sequence of the recombinant protein containing resi-
dues Met284-Gln497 of CRISPLD2 and residues derived from the
expression vector was 26,836 Da.
E. coli JM109 cells were transformed with the ligation mixture
and clones containing the insert encoding the LCCL-domains were
isolated. After sequence veriﬁcation the pPICZalphaA plasmid
containing the insert was linearized and P. pastorisGS115 cells were
transformed by electroporation. Genomic DNA was prepared from
Zeocin resistant colonies to check the insertion of the expression
plasmids into the yeast chromosome. Veriﬁed P. pastoris clones
were grown in 400 ml medium containing 2% peptone, 1% yeast
extract and 5% glycerol for 72 h then the medium was changed to
induction medium containing 100 mM potassium phosphate pH
7.5, 0.2% ammonium sulfate, 0.34% Yeast Nitrogen Base, 0.004%
histidine, 0.00004% biotin and 1% methanol; culture ﬂasks were
shaken for 48 h and methanol addition was repeated every 24 h.
The cells were centrifuged and the supernatant was applied
onto Ni-afﬁnity columns. Unbound components were removed by
washing the columnwith ten column volumes of 20 mM TRISeHCl
buffer, pH 7.9 containing 500 mM NaCl and 30 mM imidazole and
the bound proteins were eluted with 20 mM TRISeHCl buffer, pH
7.9 containing 300mM imidazole andwith 20mMTRISeHCl buffer,
pH 7.9 containing 300 mM imidazole and 500 mM NaCl.
SDS-PAGE analysis of the elution fractions revealed that the
fractions contained two forms of the recombinant protein: a pro-
teinwithw18 kDamolecular weight was eluted with 20mM TRISe
HCl buffer, pH 7.9 containing 300 mM imidazole, while aw30 kDa
protein was eluted with 20 mM TRISeHCl buffer, pH 7.9 containing
300 mM imidazol and 500 mM NaCl.
The w30 kDa protein was further puriﬁed by Sephacryl S-200
chromatography in 50 mM phosphate buffer, pH 7.0 containing




Fig. 1. Domain architecture of human CRISPLD2 protein and the structure of the re-
combinant proteins containing its constituent LCCL-domains. The ﬁgure shows the
domain architecture of human CRISPLD2 protein deﬁned by Pfam (http://pfam.sanger.
ac.uk/). The positions of the CAP-domain (residues 62e200), the two LCCL-domains
(residues 288e379 and residues 389e483) and the three recombinant proteins are
drawn to scale.
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appropriate buffer. The N-terminal amino acid sequence of the
w30 kDa protein was found to be EAEAEFMTQVVRCDTKM, (resi-
dues underlined correspond to the N-terminal sequence of CRISP-
LD2_LCCL1þ2, residues in italic come from the expression vector).
The relative position of the CRISPLD2_LCCL1þ2 protein within the
full-length CRISPLD2 protein is illustrated in Fig. 1.
The w18 kDa protein was further puriﬁed by ion exchange
chromatography on a CM-Sepharose Fast Flow column equilibrated
with 50 mM TRISeHCl buffer, pH 7.5. The protein bound to the
matrix was eluted with 200 mM NaCl, 50 mM TRISeHCl pH 7.5,
dialyzed against 0.1 M ammonium bicarbonate buffer, pH 8.0 and
lyophilized.
The N-terminal amino acid sequence of the w18 kDa protein
was found to be MVSKVKVQ. This sequence is identical with the
Met380 e Gln387 segment of CRISPLD2, indicating that proteolytic
cleavage of the Phe379-Met380 bond in the interdomain region
separating the ﬁrst and second LCCL-domains of CRISPLD2 led to
the production of the 18 kDa protein (CRISPLD2_LCCL2) containing
the second LCCL-domain. The molecular mass calculated for the
amino acid sequence of the w18 kDa protein containing residues
Met360-Gln497 of CRISPLD2 and residues derived from the
expression vector was 15,491 Da. The relative position of the
CRISPLD2_LCCL2 protein within the full-length CRISPLD2 protein is
illustrated in Fig. 1.2.5. Expression of the ﬁrst LCCL-domain of human CRISPLD2
The DNA encoding the ﬁrst LCCL-domain of CRISPLD2 (residues
Met284-Ser378 of full-length protein) was ampliﬁed with the 50
GCCGAATTCATGACCCAAGTCGTCAGATGTG 30 forward and 50 GCCTC
TAGAGAGCTGGAAGGTTTGTATTTGC 30 reverse primers from the
pPICZalphaA plasmid containing the two LCCL-domains of
CRISPLD2.
The ampliﬁed DNAwas digestedwith EcoRI and XbaI restriction
enzymes and ligated into pPICZalphaA vector digested with the
same enzymes. Although integration of the expression plasmid
into the yeast chromosome was veriﬁed by PCR, none of the P.
pastoris clones harboring the expression plasmid produced
detectable amount of the recombinant protein, therefore we have
constructed bacterial expression vectors for the expression of this
protein in E. coli.
The insert encoding the ﬁrst LCCL-domain of CRISPLD2 was
isolated from the pPICZalphaA_CRISPLD2_LCCL1 plasmid by EcoRI
and SalI digestion and ligated into pCDFDuet-1a plasmid digested
with EcoRI and XhoI (the pCDFDuet-1a plasmid was constructed
from pCDFDuet-1 by BamHI digestion and blunt-end religation in
order to modify the reading frame). The resulting expression
cassette consists of the T7lac promoter, a hexahistidine His tag and
the insert encoding the ﬁrst LCCL-domain of CRISPLD2. ThepCDFDuet-1a expression plasmid contains a streptomycin resis-
tance gene for selection of positive transformants. The molecular
mass calculated for the amino acid sequence of the recombinant
protein containing residues Met284-Ser378 of CRISPLD2 and resi-
dues derived from the expression vector was 13,351 Da.
E. coli JM109 cells were transformed with the ligation mixtures
and clones containing the LCCL-domain were isolated. After
sequence veriﬁcation E. coli BL21(DE3) cells were transformed and
protein expression in 3L 2TY medium was induced with 0.1 mM
isopropylthio-b-galactoside. Inclusion bodies were dissolved in 8 M
urea, 100 mM TRISeHCl, 5 mM EDTA, 100 mM dithioerythritol, pH
8.0 and applied on a Sephacryl S-300 column equilibrated with the
same buffer.
Fractions were analyzed by SDS-PAGE analysis and samples
containing the recombinant protein (w15 kDa) were pooled and
dialyzed two times against 3 L of 50 mM TRISeHCl buffer, pH 8.0
containing 0.5 mM EDTA, 0.1 mM phenylmethanesulfonylﬂuoride,
followed by dialysis against 3 L of 50 mM TRISeHCl buffer, pH 8.0.
Protein precipitates were removed by centrifugation and the su-
pernatant was applied onto a Ni-agarose column. The bound re-
combinant protein was eluted with 20 mM TRISeHCl buffer, pH 7.9
containing 300 mM imidazol and 500 mM NaCl. Fractions con-
taining recombinant protein were pooled, chromatographed on
Sephacryl S-200 columns equilibrated with 50 mM phosphate
buffer, pH 7.0 containing 150 mM NaCl. Fractions containing pure
recombinant protein were pooled and were stored in frozen
fractions.
The N-terminal amino acid sequence of thew15 kDa protein is
MGSSHHHHHHSQDRSEFMTQVVR; residues underlined correspond
to residues 284e289 of CRISPLD2 protein, the residues in italic
correspond to the N-terminal His-tag of the expression vector. The
relative position of CRISPLD2_LCCL1 within the full-length
CRISPLD2 protein is illustrated in Fig. 1.3. Results
Studies on the interaction of lipopolysaccharide with immobi-
lized LCCL-domains of CRISPLD2 protein by surface plasmon reso-
nance spectroscopy revealed that both CRISPLD2_LCCL1 and
CRISPLD2_LCCL2 had afﬁnity for the endotoxin (Fig. 2, Table 1.).
Assuming an effective molecular weight of 20 kDa for lipopoly-
saccharide (see section 2.3) the equilibrium dissociation constants
for the LPS-CRISPLD2_LCCL1 and LPS-CRISPLD2_LCCL2 interaction
were KD ¼ 1.48  107 M and KD ¼ 1.84  103 M, respectively. It
should be noted that CRISPLD2_LCCL1 has higher afﬁnity for lipo-
polysaccharide than CRISPLD2_LCCL2.
The CRISPLD2_LCCL1þ2 protein (containing both LCCL-
domains) had signiﬁcantly higher afﬁnity for lipopolysaccharide
than either one of the constituent domains: the equilibrium
dissociation constant of the LPS-CRISPLD2_LCCL1þ2 interaction is
characterized with a KD of 2.36  109 M (Table 1). Our observation
that the two LCCL-domains cooperate in LPS-binding probably re-
ﬂects the fact that lipopolysaccharide is a multivalent ligand, due to
the formation of aggregates.
Interestingly, CRISPLD2_LCCL1 and CRISPLD2_LCCL2 had similar
afﬁnity for the lipid A (Fig. 3, Table 2). Assuming an effective mo-
lecular weight of 1798 for lipid A the equilibrium dissociation
constants for the LA-CRISPLD2_LCCL1 and LA-CRISPLD2_LCCL2
interaction were KD ¼ 6.84  106 M and KD ¼ 4.61  106 M,
respectively.
The CRISPLD2_LCCL1þ2 protein (containing both LCCL-
domains) had orders of magnitude higher afﬁnity for Lipid A
(KD ¼ 3.33  1010 M) than either one of the constituent domains
(KD ¼ 5e7  106 M; Table 2). This observation probably indicates
Table 1
Kinetic parameters of the interaction of LPS with immobilized recombinant LCCL
domains. The rate constants of the association and dissociation reactions and the
equilibrium dissociation constants of the interactions were determined from surface
plasmon resonance measurements with the Biaevaluation software 4.0. The rate
constants of the associationwere calculated with the assumption that the molecular
mass of LPS is 20 kDa.
Proteins KD (M) ka (1/Ms) kd (1/s)
CRISPLD2_LCCL1 1.48  107 6.11  103 9.02  104
CRISPLD2_LCCL2 1.84  103 6 0.011
CRISPLD2_LCCL1þ2 2.36  109 1.34  104 3.15  105
Fig. 2. Characterization of the interaction of the LCCL-domains of human CRISPLD2
with E. coli O127:B8 serotype lipopolysaccharide by surface plasmon resonance assays.
Sensorgrams of the interactions of (A) CRISPLD2_LCCL1þ2 protein with lipopolysac-
charide (1.25 mg/ml, 2.5 mg/ml, 5 mg/ml, 12.5 mg/ml, 25 mg/ml, 50 mg/ml, 75 mg/ml and
100 mg/ml); (B), CRISPLD2_LCCL1 protein with lipopolysaccharide (50 mg/ml, 75 mg/ml
100 mg/ml, 150 mg/ml and 200 mg/ml); (C) CRISPLD2_LCCL2 protein with lipopolysac-
charide (500 mg/ml, 750 mg/ml, 1000 mg/ml, 1500 mg/ml and 2000 mg/ml). For each
experiment one set of representative data of three parallels are shown. For the sake of
clarity the concentrations of analytes are not indicated in the panel; in each case SPR
response increased parallel with the increase of analyte concentration.
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aggregates.
It is interesting to note that whereas the two LCCL-domains have
similar afﬁnity for lipid A (Table 2), their afﬁnities are markedly
different for lipopolysaccharide (Table 1), raising the question as to
how the polysaccharide moiety of lipopolysaccharide affects its
afﬁnity for these LCCL-domains.
The effective molecular weights of lipopolysaccharide and lipid
A are unknown (see Section 2.3), therefore the KD valuesdetermined for lipopolysaccharide and lipid A can’t be compared: a
simple comparison of KD values does not tell us whether the
polysaccharide moiety increases afﬁnity for CRISPLD2_LCCL1
domain or it decreases afﬁnity for the CRISPLD2_LCCL2 domain.
Comparison of dissociation rate constants of the complexes of
recombinant proteins with lipid A and lipopolysaccharide, how-
ever, does not suffer from the uncertainty of effective molecular
weights of lipid A and lipopolysaccharide. Inspection of the data in
Tables 1 and 2 clearly shows that the polysaccharide moiety in-
creases the rate of dissociation byw two orders of magnitude, from
5.63  104/s (LA-CRISPLD2_LCCL2 complex) to 0.011/s (LPS-
CRISPLD2_LCCL2 complex). In view of this observation we may
conclude that in the case of the CRISPLD2_LCCL2 domain the
polysaccharide moiety interferes with the proper binding of the
lipid A moiety.
Comparison of the dissociation rate constants of the LA-
CRISPLD2_LCCL1þ2 and LPS-CRISPLD2_LCCL1þ2 complexes also
indicates a negative inﬂuence of the polysaccharide-moiety:
whereas the LA-CRISPLD2_LCCL1þ2 complex dissociates with a
rate constant of 3.49  108/s the value for the LPS-
CRISPLD2_LCCL1þ2 complex is a thousand-fold higher,
3.15  105/s. This observation indicates that the LCCL-domains of
CRISPLD2 are more effective in binding the toxic lipid A moiety of
the endotoxin than the lipopolysaccharide.4. Discussion
In the present work we have shown that both LCCL-domains of
human CRISPLD2 have high afﬁnity for lipid A and that they are
signiﬁcantly more effective in binding the toxic lipid A moiety of
the endotoxin than lipopolysaccharide. Accordingly, it seems to be
more appropriate to describe CRISPLD2 as a lipid A-binding protein
than a lipopolysaccharide-binding protein.
In view of the structure-function aspects of lipopolysaccharide
this distinction may have important functional implications.
Lipopolysaccharides of Gram-negative bacteria are responsible
for a variety of biological effects associated with Gram-negative
sepsis. They contain three distinct regions: the lipid A moiety, the
core region and a polysaccharide portion. The lipid A moiety is the
most conserved part of endotoxin, it is highly conserved in E. coli
[7e9].
It is now well established that the lipid A moiety represents the
toxic principle of endotoxic lipopolysaccharides, whereas their
more variable polysaccharide regions are primarily responsible for
their immunogenic, antigenic properties [10]. LPS is recognized by
the Toll-like receptor TLR4-MD-2 complex, lipid A is the crucial
moiety in this interaction: ﬁve of the six lipid chains of lipid A are
inserted into a deep hydrophobic pocket of MD-2, whereas the
sixth lipid chain interacts with TLR4 [11].
Since phagocytic cells have enzymes that deacylate the toxic
lipid A moiety of lipopolysaccharide they may detoxify it without
destroying its immunogenicity or antigenicity. As a corollary,
Table 2
Kinetic parameters of the interaction of diphosphoryl lipid A with immobilized re-
combinant LCCL-domains. The rate constants of the association and dissociation
reactions and the equilibrium dissociation constants of the interactions were
determined from surface plasmon resonance measurements with the Biaevaluation
software 4.0. The rate constants of the association were calculated with a molecular
mass of 1798 Da.
Proteins KD (M) ka (1/Ms) kd (1/s)
CRISPLD2_LCCL1 6.84  106 127 8.71  104
CRISPLD2_LCCL2 4.61  106 122 5.63  104
CRISPLD2_LCCL1þ2 3.33  1010 105 3.49  108
Fig. 3. Characterization of the interaction of the LCCL-domains of human CRISPLD2
with diphosphoryl lipid A by surface plasmon resonance assays. Sensorgrams of the
interactions of (A) CRISPLD2_LCCL1þ2 protein with diphosphoryl lipid A (5 mg/ml,
9 mg/ml, 18 mg/ml, 36 mg/ml and 48 mg/ml); (B), CRISPLD2_LCCL1 protein with
diphosphoryl Lipid A (36 mg/ml, 72 mg/ml, 144 mg/ml and 216 mg/ml); (C)
CRISPLD2_LCCL2 protein with diphosphoryl Lipid A (72 mg/ml, 216 mg/ml and 288 mg/
ml). For each experiment one set of representative data of three parallels are shown.
For the sake of clarity the concentrations of analytes are not indicated in the panel; in
each case SPR response increased parallel with the increase of analyte concentration.
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immunogenic and antigenic properties may prevent excessive in-
ﬂammatory response while promoting the development of anti-
bacterial immunity [12].
The fact that the LCCL-domains of CRISPLD2 are speciﬁc for the
toxic lipid A moiety of the endotoxin suggests that CRISPLD2 may
effectively block the interaction between endotoxins and the TLR4-
MD-2 complex, thereby blocking LPS-induced pro-inﬂammatory
signaling. We note with interest that a recent study on chronic
obstructive pulmonary disease (COPD) has identiﬁed the CRISPLD2gene among the genes that are induced in human airway epithelial
cells by the anti-inﬂammatory adenosine A2B-receptor agonist Bay
60-6583 [13]. This observation suggests that the enhanced expres-
sion of CRISPLD2, a lipid A antagonist, could help reduce exacer-
bations of COPD caused by infection with gram-negative bacteria.
The anti-inﬂammatory function of CRISPLD2 protein may also
have relevance for the role of CRISPLD2 (also known as LGL1) in
various developmental processes.
Recent studies suggest that the CRISPLD2 gene might be
involved in the etiology of non-syndromic cleft lip and palate
(NSCLP) [14e17]. Strong support for the involvement of the
CRISPLD2 gene in the etiology of NSCLP was provided in a recent
study that has shown that knock down of the crispld2 gene in
zebraﬁsh disturbed palate and jaw formation [18]. Practically
nothing is known, however, as to how loss of CRISPLD2 protein
might contribute to craniofacial malformations.
In view of the anti-inﬂammatory function of CRISPLD2 protein it
seems possible that mutations affecting the CRISPLD2 gene increase
the risk of NSCLP since they decrease the level of this lipid A
antagonist, thereby increasing the chance of inﬂammation caused
by infection with gram-negative bacteria. According to this inter-
pretation the role of the CRISPLD2 gene in NSCLP reﬂects the fact
that CRISPLD2 is an anti-inﬂammatory protein. The observation
that infection and maternal fever during early pregnancy increase
the risk of NSCLP [19,20] is in harmony with this interpretation.
Several studies have addressed the role of LGL1/CRISPLD2 in lung
development. Oyewumi et al. [21] have shown that antisense oli-
godeoxynucleotides that decrease Lgl1 mRNA and protein levels
inhibit branching morphogenesis in fetal rat lung. Studies on Lgl1þ/
 mice have also conﬁrmed that the Lgl1 protein is required for
developmental processes that precede lung formation [22]. Lgl1þ/
mice were found to display a complex phenotype characterized by
delayed histological maturation, features of inﬂammation in the
post-natal period andaltered lungmechanics atmaturity. Since LGL1
protein (i.e. CRISPLD2 protein) is a lipid A-binding protein it seems
plausible to assume that the decreased levels of the protein in Lgl1þ/
mice may explain their increased sensitivity to inﬂammation.
Similarly, the role of LGL1 in lung morphogenesis may also be
related to its molecular function as a lipid A antagonist. It is now
well established that morphogenesis of fetal lung is severely
affected by inﬂammation induced by endotoxin [23e26], therefore
it seems likely that LGL1 exerts its inﬂuence on morphogenesis
through the inhibition of Toll-like receptor signaling. In harmony
with this interpretation loss of Lgl1 [27] or induction of Toll-
signaling by endotoxin [26] have similar effects on fetal lung
development: inhibition of distal airway branching and alveolari-
zation through disruption of epithelialemesenchymal interactions.Acknowledgments
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